Skip Nav Destination
Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis
Issue Archive
June 23 2016
Table of Contents
BLOOD FLASHBACK
INSIDE BLOOD COMMENTARIES
PERSPECTIVES
BLOOD SPOTLIGHT
REVIEW ARTICLE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype
Clinical Trials & Observations
Julie Toubiana,on behalf of the International STAT1 Gain-of-Function Study Group,Satoshi Okada,on behalf of the International STAT1 Gain-of-Function Study Group,Julia Hiller,on behalf of the International STAT1 Gain-of-Function Study Group,Matias Oleastro,on behalf of the International STAT1 Gain-of-Function Study Group,Macarena Lagos Gomez,on behalf of the International STAT1 Gain-of-Function Study Group,Juan Carlos Aldave Becerra,on behalf of the International STAT1 Gain-of-Function Study Group,Marie Ouachée-Chardin,on behalf of the International STAT1 Gain-of-Function Study Group,Fanny Fouyssac,on behalf of the International STAT1 Gain-of-Function Study Group,Katta Mohan Girisha,on behalf of the International STAT1 Gain-of-Function Study Group,Amos Etzioni,on behalf of the International STAT1 Gain-of-Function Study Group,Joris Van Montfrans,on behalf of the International STAT1 Gain-of-Function Study Group,Yildiz Camcioglu,on behalf of the International STAT1 Gain-of-Function Study Group,Leigh Ann Kerns,on behalf of the International STAT1 Gain-of-Function Study Group,Bernd Belohradsky,on behalf of the International STAT1 Gain-of-Function Study Group,Stéphane Blanche,on behalf of the International STAT1 Gain-of-Function Study Group,Aziz Bousfiha,on behalf of the International STAT1 Gain-of-Function Study Group,Carlos Rodriguez-Gallego,on behalf of the International STAT1 Gain-of-Function Study Group,Isabelle Meyts,on behalf of the International STAT1 Gain-of-Function Study Group,Kai Kisand,on behalf of the International STAT1 Gain-of-Function Study Group,Janine Reichenbach,on behalf of the International STAT1 Gain-of-Function Study Group,Ellen D. Renner,on behalf of the International STAT1 Gain-of-Function Study Group,Sergio Rosenzweig,on behalf of the International STAT1 Gain-of-Function Study Group,Bodo Grimbacher,on behalf of the International STAT1 Gain-of-Function Study Group,Frank L. van de Veerdonk,on behalf of the International STAT1 Gain-of-Function Study Group,Claudia Traidl-Hoffmann,on behalf of the International STAT1 Gain-of-Function Study Group,Capucine Picard,on behalf of the International STAT1 Gain-of-Function Study Group,Laszlo Marodi,on behalf of the International STAT1 Gain-of-Function Study Group,Tomohiro Morio,on behalf of the International STAT1 Gain-of-Function Study Group,Masao Kobayashi,on behalf of the International STAT1 Gain-of-Function Study Group,Desa Lilic,on behalf of the International STAT1 Gain-of-Function Study Group,Joshua D. Milner,on behalf of the International STAT1 Gain-of-Function Study Group,Steven Holland,on behalf of the International STAT1 Gain-of-Function Study Group,Jean-Laurent Casanova,on behalf of the International STAT1 Gain-of-Function Study Group,Anne Puel,on behalf of the International STAT1 Gain-of-Function Study Group
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Clinical Trials & Observations
Bruno Paiva,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Maria-Teresa Cedena,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Noemi Puig,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Paula Arana,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Maria-Belen Vidriales,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Lourdes Cordon,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Juan Flores-Montero,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Norma C. Gutierrez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,María-Luisa Martín-Ramos,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Joaquin Martinez-Lopez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Enrique M. Ocio,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Miguel T. Hernandez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Ana-Isabel Teruel,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Laura Rosiñol,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,María-Asunción Echeveste,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Rafael Martinez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Mercedes Gironella,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Albert Oriol,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Carmen Cabrera,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Jesus Martin,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Joan Bargay,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Cristina Encinas,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Yolanda Gonzalez,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Jacques J. M. Van Dongen,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Alberto Orfao,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Joan Bladé,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Maria-Victoria Mateos,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Juan José Lahuerta,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,Jesús F. San Miguel,on behalf of the Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Aneta Schieferdecker,Anna Oberle,Benjamin Thiele,Fabian Hofmann,Markus Göthel,Sebastian Miethe,Michael Hust,Friederike Braig,Mareike Voigt,Ute-Marie von Pein,Friedrich Koch-Nolte,Friedrich Haag,Malik Alawi,Daniela Indenbirken,Adam Grundhoff,Carsten Bokemeyer,Ulrike Bacher,Nicolaus Kröger,Mascha Binder
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Mary Ann Anderson,Jing Deng,John F. Seymour,Constantine Tam,Su Young Kim,Joshua Fein,Lijian Yu,Jennifer R. Brown,David Westerman,Eric G. Si,Ian J. Majewski,David Segal,Sari L. Heitner Enschede,David C. S. Huang,Matthew S. Davids,Anthony Letai,Andrew W. Roberts
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu-Tzu Tai,Chirag Acharya,Gang An,Michele Moschetta,Mike Y. Zhong,Xiaoyan Feng,Michele Cea,Antonia Cagnetta,Kenneth Wen,Hans van Eenennaam,Andrea van Elsas,Lugui Qiu,Paul Richardson,Nikhil Munshi,Kenneth C. Anderson
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Guang Yang,Sara J. Buhrlage,Li Tan,Xia Liu,Jie Chen,Lian Xu,Nicholas Tsakmaklis,Jiaji G. Chen,Christopher J. Patterson,Jennifer R. Brown,Jorge J. Castillo,Wei Zhang,Xiaofeng Zhang,Shuai Liu,Philip Cohen,Zachary R. Hunter,Nathanael Gray,Steven P. Treon
MYELOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Programming of donor T cells using allogeneic δ-like ligand 4–positive dendritic cells to reduce GVHD in mice
Kazuhiro Mochizuki,Lijun Meng,Izumi Mochizuki,Qing Tong,Shan He,Yongnian Liu,Janaki Purushe,Henry Fung,M. Raza Zaidi,Yanyun Zhang,Ran Reshef,Bruce R. Blazar,Hideo Yagita,Shin Mineishi,Yi Zhang
The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis
Clinical Trials & Observations
Bernd Hartz,Rebecca Marsh,Kanchan Rao,Jan-Inge Henter,Michael Jordan,Lisa Filipovich,Peter Bader,Rita Beier,Birgit Burkhardt,Roland Meisel,Ansgar Schulz,Beate Winkler,Michael H. Albert,Johann Greil,Gülsün Karasu,Wilhelm Woessmann,Selim Corbacioglu,Bernd Gruhn,Wolfgang Holter,Jörn-Sven Kühl,Peter Lang,Markus G. Seidel,Paul Veys,Alexandra Löfstedt,Sandra Ammann,Stephan Ehl,Gritta Janka,Ingo Müller,Kai Lehmberg
BLOOD WORK
-
Cover Image
Cover Image
Determination of myeloperoxidase (MPO) activity by immunocytochemistry on a peripheral blood smear of a patient with myelofibrosis and acquired MPO deficiency. Brown precipitates represent MPO-positive granules. The image shows an MPO-positive and an MPO-deficient neutrophil granulocyte. MPO-deficient neutrophil granulocytes carry a homozygous calreticulin mutation. See the article by Theocharides et al on page 3253.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals